Alcohol Plus Additional Risk Factors: Rodent Model of Liver Injury

Area of Science:

• Hepatology
• Toxicology
• Animal Models

Background:

• Alcohol-associated liver disease (ALD) is a major global health concern, encompassing conditions from steatosis to hepatocellular carcinoma (HCC).
• Numerous factors beyond alcohol consumption, including genetic predispositions (e.g., ALDH2 deficiency), lifestyle choices (smoking, high-fat diet), and infections, contribute to ALD.
• Understanding how alcohol interacts with these additional risk factors to exacerbate liver injury remains a critical knowledge gap.

Purpose of the Study:

• To review and present rodent models (EtOH + "X") that simulate the combined effects of alcohol and other risk factors on liver injury.
• To explore the synergistic interactions between alcohol and additional risk factors in the context of ALD.
• To provide a more reliable platform for studying ALD mechanisms and developing therapeutic strategies.

Main Methods:

• Summarizing existing literature on rodent models combining ethanol (EtOH) exposure with other risk factors ("X").
• Detailing the methodologies used in creating these combined-exposure rodent models.
• Identifying and discussing relevant indicators of liver injury within these models.

Main Results:

• These EtOH + "X" rodent models effectively simulate the exacerbation of liver injury seen in human ALD patients exposed to multiple risk factors.
• The models facilitate deeper investigation into the synergistic mechanisms underlying alcohol-induced liver damage when combined with other insults.
• They offer a valuable tool for dissecting the molecular targets and pathways involved in combined alcohol and "X"-induced liver injury.

Conclusions:

• Rodent models of EtOH + "X" are crucial for advancing our understanding of complex ALD pathogenesis.
• These models provide a more accurate simulation of human ALD, enabling better study of disease mechanisms.
• Further research using these models can accelerate the development of targeted therapies for alcohol-associated liver disease.